ID   RL95-2
AC   CVCL_0505
SY   RL95_2; RL-95-2; RL-952; RL952; RL95
DR   BTO; BTO:0004491
DR   CLO; CLO_0008830
DR   EFO; EFO_0002320
DR   MCCL; MCC:0000402
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-1671
DR   BCRC; 60103
DR   BCRJ; 0366
DR   BioGRID_ORCS_Cell_line; 999
DR   BioSample; SAMN03473219
DR   BioSample; SAMN10987787
DR   cancercelllines; CVCL_0505
DR   CCRID; 3101HUMTCHu198
DR   CCRID; 4201HUM-CCTCC00113
DR   CCTCC; GDC0113
DR   Cell_Model_Passport; SIDM01088
DR   ChEMBL-Cells; CHEMBL3308843
DR   ChEMBL-Targets; CHEMBL2366168
DR   CLS; 305062
DR   Cosmic; 713477
DR   Cosmic; 713489
DR   Cosmic; 809132
DR   Cosmic; 846175
DR   Cosmic; 871556
DR   Cosmic; 889117
DR   Cosmic; 930082
DR   Cosmic; 980637
DR   Cosmic; 1007165
DR   Cosmic; 1066226
DR   Cosmic; 1070808
DR   Cosmic; 1102377
DR   Cosmic; 1177623
DR   Cosmic; 1223487
DR   Cosmic; 1576464
DR   Cosmic; 1622899
DR   Cosmic; 1696756
DR   Cosmic; 2030481
DR   Cosmic; 2301551
DR   Cosmic; 2646617
DR   Cosmic; 2702441
DR   Cosmic-CLP; 930082
DR   DepMap; ACH-000965
DR   EGA; EGAS00001000978
DR   GDSC; 930082
DR   GEO; GSM374977
DR   GEO; GSM375436
DR   GEO; GSM844677
DR   GEO; GSM887542
DR   GEO; GSM888625
DR   GEO; GSM1670382
DR   GEO; GSM3161728
DR   GEO; GSM3161729
DR   IARC_TP53; 1114
DR   IGRhCellID; RL952
DR   KCB; KCB 2013033YJ
DR   LiGeA; CCLE_166
DR   LINCS_LDP; LCL-1506
DR   Lonza; 1501
DR   PharmacoDB; RL952_1319_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0505
DR   PubChem_Cell_line; CVCL_0505
DR   Wikidata; Q54950589
RX   PubMed=1541432;
RX   PubMed=2436984;
RX   PubMed=6339371;
RX   PubMed=7798295;
RX   PubMed=8123477;
RX   PubMed=9887230;
RX   PubMed=12893190;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20944090;
RX   PubMed=22460905;
RX   PubMed=22710073;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31395879;
RX   PubMed=33174010;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: TCGA-110-CL cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 22 hours (PubMed=1541432).
CC   HLA typing: A*02:10,24:02; B*55:01,55:01; C*03:03,03:03; DQA1*01:02,05:02; DQB1*05:03,05:03; DRB1*14:01,14:01 (PubMed=26589293).
CC   Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger).
CC   Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Arg693Ter (c.2077C>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gln61His (c.183G>T); ClinVar=VCV000376318; Zygosity=Heterozygous (ATCC; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Arg1252Ter (c.3754C>T); ClinVar=VCV000167228; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asn323fs*2 (c.968_969insA); Zygosity=Heterozygous (PubMed=20944090).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asn323Metfs*21 (c.968delA); ClinVar=VCV000653412; Zygosity=Heterozygous (PubMed=20944090).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val73Trpfs*50 (c.216delC) (p.P72fs); ClinVar=VCV000428897; Zygosity=Heterozygous (PubMed=9887230; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Heterozygous (PubMed=9887230; Cosmic-CLP; DepMap).
CC   Omics: Chromatin accessibility by ATAC-seq.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0.33%; East Asian, North=1.49%; East Asian, South=0%; South Asian=1.52%; European, North=68.38%; European, South=28.28% (PubMed=30894373).
CC   Derived from site: In situ; Endometrium; UBERON=UBERON_0001295.
ST   Source(s): ATCC; Cosmic-CLP; Genomics_Center_BCF_Technion; PubMed=25877200; PubMed=33174010
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D10S1248: 14,15
ST   D12S391: 15,21
ST   D13S317: 8,12
ST   D16S539: 11,13
ST   D18S51: 10,14
ST   D19S433: 15
ST   D1S1656: 13,19.3
ST   D21S11: 28,29
ST   D22S1045: 15
ST   D2S1338: 22,23
ST   D2S441: 11,14
ST   D3S1358: 14,16
ST   D5S818: 10,11
ST   D7S820: 10
ST   D8S1179: 10,14
ST   FGA: 20,22
ST   Penta D: 9
ST   Penta E: 5,11
ST   TH01: 9,9.3
ST   TPOX: 8
ST   vWA: 16,20
DI   NCIt; C114656; Endometrial adenosquamous carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   65Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 40
//
RX   PubMed=1541432; DOI=10.1016/0090-8258(92)90045-K;
RA   Rantanen V., Grenman S.E., Kulmala J., Salmi T., Grenman R.;
RT   "Radiation sensitivity of endometrial carcinoma in vitro.";
RL   Gynecol. Oncol. 44:217-222(1992).
//
RX   PubMed=2436984; DOI=10.1016/0090-8258(87)90286-1;
RA   Noumoff J.S., Haydock S.W., Sachdeva R., Heyner S., Pritchard M.L.;
RT   "Characteristics of cell lines derived from normal and malignant
RT   endometrial tissue.";
RL   Gynecol. Oncol. 27:141-149(1987).
//
RX   PubMed=6339371; DOI=10.1007/BF02618053;
RA   Way D.L., Grosso D.S., Davis J.R., Surwit E.A., Christian C.D.;
RT   "Characterization of a new human endometrial carcinoma (RL95-2)
RT   established in tissue culture.";
RL   In Vitro 19:147-158(1983).
//
RX   PubMed=7798295; DOI=10.1007/BF01194268;
RA   Rantanen V., Grenman S.E., Kulmala J., Alanen K., Lakkala T.,
RA   Grenman R.;
RT   "Sublethal damage repair after fractionated irradiation in endometrial
RT   cancer cell lines tested with the 96-well plate clonogenic assay.";
RL   J. Cancer Res. Clin. Oncol. 120:712-716(1994).
//
RX   PubMed=8123477; DOI=10.1038/bjc.1994.87;
RA   Rantanen V., Grenman S.E., Kulmala J., Grenman R.;
RT   "Comparative evaluation of cisplatin and carboplatin sensitivity in
RT   endometrial adenocarcinoma cell lines.";
RL   Br. J. Cancer 69:482-486(1994).
//
RX   PubMed=9887230; DOI=10.1006/gyno.1998.5194;
RA   Rantanen V., Grenman S.E., Kurvinen K., Hietanen S., Raitanen M.,
RA   Syrjanen S.M.;
RT   "p53 mutations and presence of HPV DNA do not correlate with
RT   radiosensitivity of gynecological cancer cell lines.";
RL   Gynecol. Oncol. 71:352-358(1998).
//
RX   PubMed=12893190; DOI=10.1016/s0090-8258(03)00335-4;
RA   Tanaka R., Saito T., Ashihara K., Nishimura M., Mizumoto H., Kudo R.;
RT   "Three-dimensional coculture of endometrial cancer cells and
RT   fibroblasts in human placenta derived collagen sponges and expression
RT   matrix metalloproteinases in these cells.";
RL   Gynecol. Oncol. 90:297-304(2003).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20944090; DOI=10.1126/scitranslmed.3001538;
RA   Dedes K.J., Wetterskog D., Mendes-Pereira A.M., Natrajan R.,
RA   Lambros M.B., Geyer F.C., Vatcheva R., Savage K., Mackay A.,
RA   Lord C.J., Ashworth A., Reis-Filho J.S.;
RT   "PTEN deficiency in endometrioid endometrial adenocarcinomas predicts
RT   sensitivity to PARP inhibitors.";
RL   Sci. Transl. Med. 2:53ra75.1-53ra75.8(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017;
RA   Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K.,
RA   Lessey B.A., Jordan V.C., Bradford A.P.;
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31395879; DOI=10.1038/s41467-019-11415-2;
RA   Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M.,
RA   van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.;
RT   "Comprehensive transcriptomic analysis of cell lines as models of
RT   primary tumors across 22 tumor types.";
RL   Nat. Commun. 10:3574.1-3574.11(2019).
//
RX   PubMed=33174010; DOI=10.3892/ijo.2020.5139;
RA   Devor E.J., Gonzalez-Bosquet J., Thiel K.W., Leslie K.K.;
RT   "Genomic characterization of five commonly used endometrial cancer
RT   cell lines.";
RL   Int. J. Oncol. 57:1348-1357(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//